[HTML] sciencedirect.com

[HTML][HTML] Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803)

YL Wu, C Zhou, Y Cheng, S Lu, GY Chen, C Huang… - Annals of …, 2013 - Elsevier
Background This phase II, open-label study evaluated the efficacy and safety of erlotinib as
second-line therapy in non-small-cell lung cancer (NSCLC) patients with brain metastases …
被引用次数：276 相关文章

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803)

YL Wu, C Zhou, Y Cheng, S Lu, GY Chen… - Annals of …, 2013 - annalsofoncology.org
Background This phase II, open-label study evaluated the efficacy and safety of erlotinib as
second-line therapy in non-small-cell lung cancer (NSCLC) patients with brain metastases …

[引用][C] Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803)

YL Wu, C Zhou, Y Cheng, S Lu, GY Chen, C Huang… - Annals of …, 2013 - cir.nii.ac.jp
Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and
asymptomatic brain metastases: a phase II study (CTONG–0803) | CiNii Research CiNii 国立 …

[引用][C] Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803)

YL WU, C ZHOU, Y CHENG, S LU, GY CHEN… - Annals of …, 2013 - jglobal.jst.go.jp
Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and
asymptomatic brain metastases: a phase II study (CTONG-0803) | Article Information | J-GLOBAL …
[PDF] researchgate.net

[PDF][PDF] Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803)

YL Wu, C Zhou, Y Cheng, S Lu, GY Chen… - Annals of …, 2013 - researchgate.net
Background: This phase II, open-label study evaluated the efficacy and safety of erlotinib as
second-line therapy in non-small-cell lung cancer (NSCLC) patients with brain metastases …

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803)

YL Wu, C Zhou, Y Cheng, S Lu… - Annals of oncology …, 2013 - pubmed.ncbi.nlm.nih.gov
Background This phase II, open-label study evaluated the efficacy and safety of erlotinib as
second-line therapy in non-small-cell lung cancer (NSCLC) patients with brain metastases …

[引用][C] Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG―0803)

YL WU, C ZHOU, JJ YANG, Y CHENG, S LU… - Annals of …, 2013 - pascal-francis.inist.fr
Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and
asymptomatic brain metastases: a phase II study (CTONG―0803) CNRS Inist Pascal-Francis …

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).

YL Wu, C Zhou, Y Cheng, S Lu, GY Chen… - Annals of Oncology …, 2012 - europepmc.org
Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and
asymptomatic brain metastases: a phase II study (CTONG-0803). - Abstract - Europe PMC Sign …

[引用][C] Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG―0803)

YL WU, C ZHOU, Y CHENG, S LU… - Annals of …, 2013 - Oxford University Press